Literature DB >> 20583850

Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study.

Martine T E Puts1, Johanne Monette, Veronique Girre, Beatriz Costa-Lima, Christina Wolfson, Gerald Batist, Howard Bergman.   

Abstract

INTRODUCTION: Older cancer patients are possibly at an increased risk of medication-related problems because, typically, they receive many medications during their cancer treatment, both for the cancer itself and for supportive care.
OBJECTIVES: The aim of this study was to describe the number and severity of potential medication problems during treatment of cancer in the first year after diagnosis. We also sought to examine whether patients receiving systemic cancer treatment had more medication-related problems at 3, 6 and 12 months than those not receiving systemic cancer treatment.
METHODS: This was a prospective pilot cohort study on health and vulnerability in older newly diagnosed cancer patients with 1-year follow-up. The study was conducted at Segal Cancer Centre, Jewish General Hospital, Montreal, Canada. Of 156 eligible patients, 112 agreed to participate (response 71.8%). The patients were aged >or=65 years and were newly diagnosed with breast, colorectal or lung cancer, lymphoma or multiple myeloma. Patients were asked for permission to obtain their list of medications from their pharmacist. The cancer treatment information was abstracted from the medical chart. Vigilance Santé software was used to identify the presence, type and severity of potential medication problems.
RESULTS: The median number of medications was five at baseline, seven at 3 months and six at 6 and 12 months. At baseline, 247 potential medication problems were identified, followed by 273 at 3 months, 229 at 6 months and 188 at 12 months. About half of the patients at each follow-up had one or more moderate or severe potential medication problem. Patients receiving systemic cancer treatment had significantly fewer potential problems at 3 months than patients not receiving systemic cancer treatment, but no differences were observed at 6 and 12 months. The most common warnings were contraindications, interactions and miscellaneous warnings, and the cancer treatment was involved in 12% of all potential problems.
CONCLUSION: This study showed that the majority of older newly diagnosed cancer patients take prescribed medication and about two-thirds have potential medication problems, of which about half are of at least moderate severity. The cancer treatment was involved in only a small proportion of all potential drug problems.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20583850     DOI: 10.2165/11537310-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  40 in total

Review 1.  Drug interactions in cancer therapy.

Authors:  Charity D Scripture; William D Figg
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

Review 2.  A systematic review on drug interactions in oncology.

Authors:  Rachel P Riechelmann; Everardo D Saad
Journal:  Cancer Invest       Date:  2006-11       Impact factor: 2.176

Review 3.  Pharmacology of antineoplastic medications in older cancer patients.

Authors:  Lodovico Balducci
Journal:  Oncology (Williston Park)       Date:  2009-01       Impact factor: 2.990

Review 4.  Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening.

Authors:  Nagi B Kumar; Kathy Allen; Heather Bell
Journal:  Cancer Control       Date:  2005-07       Impact factor: 3.302

5.  Treatment and referral patterns for colorectal cancer.

Authors:  Susan A Oliveria; Marianne Ulcickas Yood; Ulka B Campbell; Steven M Yood; Paul Stang
Journal:  Med Care       Date:  2004-09       Impact factor: 2.983

6.  Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology-acute care for elders unit.

Authors:  Kellie L Flood; Maria B Carroll; Cyndi V Le; Cynthia J Brown
Journal:  Am J Geriatr Pharmacother       Date:  2009-06

7.  Potential drug interactions and duplicate prescriptions among cancer patients.

Authors:  Rachel P Riechelmann; Ian F Tannock; Lisa Wang; Everardo D Saad; Nathan A Taback; Monika K Krzyzanowska
Journal:  J Natl Cancer Inst       Date:  2007-04-18       Impact factor: 13.506

8.  Dietary supplement use in individuals living with cancer and other chronic conditions: a population-based study.

Authors:  Melissa Farmer Miller; Keith M Bellizzi; Meryl Sufian; Anita H Ambs; Michael S Goldstein; Rachel Ballard-Barbash
Journal:  J Am Diet Assoc       Date:  2008-03

Review 9.  The challenge of managing drug interactions in elderly people.

Authors:  Louise Mallet; Anne Spinewine; Allen Huang
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321

10.  Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population?

Authors:  Jacqueline L Green; Jonathan N Hawley; Kimberly J Rask
Journal:  Am J Geriatr Pharmacother       Date:  2007-03
View more
  8 in total

1.  The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).

Authors:  Kathleen Elliot; Janet A Tooze; Rachel Geller; Bayard L Powell; Timothy S Pardee; Ellen Ritchie; LeAnne Kennedy; Kathryn E Callahan; Heidi D Klepin
Journal:  Leuk Res       Date:  2014-07-07       Impact factor: 3.156

Review 2.  Application of drug-related problem (DRP) classification systems: a review of the literature.

Authors:  Benjamin J Basger; Rebekah J Moles; Timothy F Chen
Journal:  Eur J Clin Pharmacol       Date:  2014-05-02       Impact factor: 2.953

Review 3.  Treatment of Older Patients with Acute Lymphoblastic Leukaemia.

Authors:  Nicola Gökbuget
Journal:  Drugs Aging       Date:  2018-01       Impact factor: 3.923

Review 4.  How to implement a geriatric assessment in your clinical practice.

Authors:  Schroder Sattar; Shabbir M H Alibhai; Hans Wildiers; Martine T E Puts
Journal:  Oncologist       Date:  2014-09-03

5.  Potential drug-drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospective cohort study.

Authors:  Paula Stoll; Luciane Kopittke
Journal:  Int J Clin Pharm       Date:  2015-02-25

6.  Network analysis of drug-related problems in hospitalized patients with hematologic malignancies.

Authors:  Myeong Gyu Kim; Chae Reen Jeong; Hyun Jee Kim; Jae Hyun Kim; Yun-Kyoung Song; Kyung Im Kim; Eunhee Ji; Sung-Soo Yoon; Youngil Koh; Yoon-Sook Cho; In-Wha Kim; Jung Mi Oh
Journal:  Support Care Cancer       Date:  2018-02-27       Impact factor: 3.603

7.  Pilot Randomized Trial of a Pharmacy Intervention for Older Adults with Cancer.

Authors:  Ryan D Nipp; Margaret Ruddy; Charn-Xin Fuh; Mark L Zangardi; Christine Chio; E Bridget Kim; Barbara Kong Mui Li; Ying Long; Gayle C Blouin; Daniel Lage; David P Ryan; Joseph A Greer; Areej El-Jawahri; Jennifer S Temel
Journal:  Oncologist       Date:  2018-10-19

8.  The fall rate of older community-dwelling cancer patients.

Authors:  Martine T E Puts; Johanne Monette; Veronique Girre; Christina Wolfson; Michèle Monette; Gerald Batist; Howard Bergman
Journal:  Support Care Cancer       Date:  2012-09-01       Impact factor: 3.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.